Ibogaine is rapidly gaining attention for its potential to heal veterans and others with debilitating health conditions, but this growing interest makes sustainable production a significant concern. Suppliers now race to develop ethical sources as demand climbs.
News of remarkable research on sustainable alternatives recently surfaced in a Mongabay piece this week, citing a January article from the Brazilian publication Exame.
Brazilian researcher Ricardo Marques is leading the work and guards its core secrets closely. He has identified four Amazonian plant species that produce voacangine, a precursor his company Hylaea promotes on its website for high-purity, scalable conversion into ibogaine.
Marques refuses to disclose the exact identities of these plants, even to his own family, to prevent a pharmaceutical rush that could repeat the overharvesting problems seen in Africa. He describes them only as common “weeds” that thrive in pastures.
This secrecy forms the cornerstone of his strategy. A pharmacologist and natural products chemist from Acre, Marques spent years locating the plants, studying their ecology and perfecting non-destructive harvesting methods that allow full regeneration. This differs from the root-uprooting practices used on the slow-growing African iboga shrub.
He trains local families in the Chico Mendes Extractive Reserve to collect and process the material sustainably, creating income while protecting the resource. His startup Hylaea partners with the University of São Paulo to scale production, has exported initial voacangine batches to an undisclosed American company, and develops ibogaine hydrochloride. Hylaea also made a small shipment to Israel, Marques explained. The company website stresses GMP-compliant Amazon-sourced supply for research and clinical use.
Policy tailwinds
This development in South America aligns with growing policy support in the United States. In April, President Donald Trump signed an executive order accelerating research, reviews and access pathways for psychedelics including ibogaine, supported by priority mechanisms and funding to bolster state initiatives. Texas currently leads with major investments in veteran clinical trials.
Clinics where ibogaine can be legally administered report rising guest numbers as well, especially among U.S. veterans seeking help for PTSD, traumatic brain injury and addiction. Mexican centres note steady increases, alongside programmes in Canada, Costa Rica, Portugal and Malta.
A new case report in Frontiers in Psychiatry documented sustained abstinence from severe ketamine use disorder for over 17 months following ibogaine treatment in Mexico. Other supporting studies, such as Stanford veteran research and European detoxification trials, continue to build the evidence base.
“One dose can open a window of 6 to 8 months without the desire to use opioids,” Marques told Exame, “creating an opportunity for the user to distance themselves from the problem.”
By keeping the species’ identities secret while advancing sustainable voacangine supply, Marques’ approach aims to offer a model that could help ibogaine therapy expand more responsibly.
Read more: XTL Biopharma to enter psychedelics sector with Psyga Bio takeover
—————————————————————
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
